Skip to main content
Equibles
ENTA logo

ENTA · Enanta Pharmaceuticals Inc · Analyst Estimates

Track ENTA — free

Use ENTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ENTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.94 -0.24 (-1.97%) Q2 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$354.75M
Shares
29.13M
Volume · Oct 27 319.44K Avg daily vol (3M) 243.4K

Analyst Estimates

Compare analyst forecasts for Enanta Pharmaceuticals Inc across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-09-24 07:32 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-09-30

Analyst estimates for FY ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-2.49
-2.29
-2.09
4
-2.29
-2.29
-1.91
-1.96
2
2
0
0
Revenue
USD
Publication date not stated
61.00M
64.00M
66.13M
5
 — — — — — — — —

FY ending 2027-09-30

Analyst estimates for FY ending 2027-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-3.08
-2.37
-1.75
5
-2.37
-2.37
-2.07
-1.98
2
2
0
0
Revenue
USD
Publication date not stated
53.19M
63.74M
77.00M
5
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.95
-0.77
-0.55
5
-0.77
-0.77
-0.64
-0.67
2
2
0
0
Revenue
USD
Publication date not stated
13.70M
15.72M
20.00M
5
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.48
-0.41
-0.33
2
-0.37
-0.37
-0.37
-0.37
1
1
0
0
Revenue
USD
Publication date not stated
14.50M
16.25M
18.00M
2
 — — — — — — — —
Key facts CIK 1177648 CUSIP 29251M106 13F (30d) 15 filings 15 filers Visit website Investor relations